Market Place
Sourcing Support
Eisai`s Robust Neurology Portfolio At AAN 2024
12 Apr 2024 //
PR NEWSWIRE
Eisai to Present Latest DAYVIGO CIV Data at 35th Annual SLEEP 2021 Meeting
09 Jun 2021 //
PRNEWSWIRE
Eisai’s anti-insomnia drug, Dayvigo gets approval in Hong Kong
02 Mar 2021 //
PHARMABIZ
Health Canada Authorizes DAYVIGO™ (lemborexant)
04 Feb 2021 //
GLOBENEWSWIRE
Eisai Presents New Analyses from Phase 3 Studies of DAYVIGO™ (lemborexant)
28 Aug 2020 //
PRNEWSWIRE
Eisai to Present Latest Insomnia Research, Including Data on Treatment DAYVIGO™
24 Aug 2020 //
PRNEWSWIRE
Eisai to Present Latest Insomnia Research, Including Data on New DAYVIGO™
24 Aug 2020 //
PRNEWSWIRE
Eisai Alzheimer`s Disease Pipeline Research Presented at AAIC 2020, BAN2401
24 Jul 2020 //
PRNEWSWIRE
Hong Kong Department of Health accepts Eisai’s NDA , anti-insomnia drug, Dayvigo
08 Jul 2020 //
PHARMABIZ
Eisai: New Drug Application for In-House Developed Anti-insomnia Drug Dayvigo
07 Jul 2020 //
FINANCE
Eisai to Launch In-House Developed New Anti-insomnia Drug in Japan
06 Jul 2020 //
BIOSPECTRUMASIA
Eisai Announces U.S. Availability of DAYVIGO® (lemborexant)
01 Jun 2020 //
PRNEWSWIRE
MHRA expands approval of Dysport for symptomatic treatment of focal spasticity
07 Jan 2020 //
PHARMAFILE
Pivotal Phase 3 Study of DAYVIGO for the Treatment of Insomnia: JAMA.
27 Dec 2019 //
PR NEWSWIRE
U.S. FDA Approves Eisai`s DAYVIGO for the Treatment of Insomnia
21 Dec 2019 //
PR NEWSWIRE
New Data about Eisai`s Latest Dementia Pipeline
11 Jul 2019 //
PR NEWSWIRE
Extensive Analyses of Phase 3 Data for Investigational Lemborexant
12 Jun 2019 //
PR NEWSWIRE
Eisai to Present Eight Lemborexant Posters at SLEEP 2019 Meeting
28 May 2019 //
PR NEWSWIRE
Eisai & Purdue Announce Buy Out of Purdue`s Rights in Worldwide Lemborexant
02 May 2019 //
PR NEWSWIRE
Eisai & Purdue Announce Buy Out of Purdue`s Rights for Commercialize Lemborexant
30 Apr 2019 //
PR NEWSWIRE
FDA accepts NDA for Lemborexant to treat Insomnia
12 Mar 2019 //
BIOSPECTRUMASIA
Eisai & Imbrium Announce U.S. FDA Filing Acceptance of NDA for Lemborexant
11 Mar 2019 //
PR NEWSWIRE
Eisai submits marketing authorization application for Insomnia drug
07 Mar 2019 //
BIOSPECTRUM
Eisai, Purdue Pharma declare positive results of SUNRISE 2
19 Oct 2018 //
BIOSPECTRUM ASIA
Eisai, Purdue Pharma declare positive results of SUNRISE 2
17 Oct 2018 //
BIOSPECTRUM
Eisai, Purdue reveal eye-opening data for sleep drug
06 Jun 2018 //
FIERCE BIOTECH
Eisai, Purdue to present latest Clinical Data on Lemborexant
23 May 2018 //
BIOSPECTRUM
Eisai and Purdue Pharma Announce Key Phase 1 Clinical Studies of Lemborexant
22 May 2018 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.